Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-CD38 monoclonal antibody

Isatuximab (Specialist drug)

Brand names: Sarclisa

Isatuximab is an anti-CD38 monoclonal antibody used as a specialist treatment for multiple myeloma, typically in combination with other anti-myeloma agents. It is given by intravenous infusion under haemato-oncology supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds CD38 on myeloma cells and triggers tumour cell death through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, phagocytosis and direct pro-apoptotic effects.

Prescribing in practice

  • Infusion-related reactions are common, particularly with the first infusion, so premedication and close monitoring during administration are essential.
  • Anti-CD38 antibodies interfere with blood compatibility testing, so baseline blood typing and screening should be arranged before starting.
  • Neutropenia and increased infection risk occur, and antiviral prophylaxis against herpes zoster is generally advised.

Monitoring

Monitor full blood count and for infusion reactions and infection during treatment.

Counselling the patient

  • Infusion reactions are most likely with the first dose; report flushing, breathlessness or chills to staff straight away.
  • Carry information that you are receiving an anti-CD38 antibody, as it can affect blood crossmatch results for some time.
  • Report fever or signs of infection promptly.

Evidence & guidelines

The ICARIA-MM and IKEMA trials demonstrated benefit of isatuximab-based combinations in relapsed or refractory multiple myeloma.

Reference: NICE TA658; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways